$9.13
-0.60-6.17%
Last update: Oct 30, 7:42 PM
Bicara Therapeutics Inc (BCAX) Stock Price, Quote, News & History
BCAXNASDAQ
Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
You can purchase shares of Bicara Therapeutics (NASDAQ:BCAX) through any online brokerage.
Other companies in Bicara Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Bicara Therapeutics has a consensus price target of $31.00.
The stock price for Bicara Therapeutics (NASDAQ: BCAX) is $8.9794 last updated October 30, 2026 at 7:42 PM EDT.
There are no upcoming dividends for Bicara Therapeutics.
Bicara Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Bicara Therapeutics.
Bicara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets,...
